

Figure 4: Risk-benefit analysis. summary of the evidence provided by the data in favor of benefit (red), as opposed to risk (blue). A value larger than one means a favorable benefit-risk ratio. A: Docetaxel; B: Nimotuzumab; C: Racotumomab.

Copyright: ©2021 Hernández M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Glob Surg, 2021 doi: 10.15761/GOS.1000230 Volume 7: 1-1